ClinicalTrials.gg
RecruitingNCT07224373ZENITHUpdated Nov 17, 2026

An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

A Phase 1 interventional study of AZD0120 - Regimen 1 and AZD0120 - Regimen 2 in Multiple Sclerosis, sponsored by AstraZeneca. Recruiting at 20 sites in 5 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 17, 2026Eligibility revisedPrimary outcomes revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,192 studies in Multiple Sclerosis with a site in United States — 184 open to participants now, 259 under way, 23 of them phase 3. Multiple Sclerosis · United States.

Planned enrollment
620th of 879
24 · median 50
Started
2025
with 56 others
Phase 1
105 of 1,192
18 open now
Primary completion
2028-12
later than 193 of 256 live
Registered
1,132nd of 1,192
by date

Among the 1,192 studies in Multiple Sclerosis with a site in United States, this one is the 620th largest by planned enrollment of the 879 interventional ones that give a count, is one of 57 that started in 2025, is one of 105 in phase 1, reaches primary completion later than 193 of the 256 other live ones, and was the 1,132nd registered.

Multiple Sclerosis

3,272 studies on the registry are indexed under Multiple Sclerosis; 664 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

184 of the 1,192 studies in Multiple Sclerosis with a site in United States are open now. Recruiting first, the newest first:

179 more — sign in →

All 184 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 432 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 213 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,192 studies in Multiple Sclerosis with a site in United States, or all of them as a file.
02

Study summary

This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with relapsing and progessive Multiple Sclerosis.

Read the detailed description

This study will evaluate AZD0120 for safety, including DLTs and TEAEs, by the SRC for determination of the Recommended Phase 2 dose for RMS and PMS disease cohorts.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • AZD0120
  • Multiple Sclerosis
  • MS
  • RMS
  • PMS
04

Who can participate

The criteria were revised on the registry on Nov 17, 2026. See what changed

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

Age

  1. Age ≥ 18-years-old to ≤ 60-years-old at the time of consent

    Type of Participant and Disease Characteristics

  2. Written in accordance with federal, local, and institutional guidelines
  3. Adequate physiological function and reserve at screening

    RMS Cohort Specific Inclusion Criteria

  4. Diagnosis of RMS according to the 2024 McDonald Criteria (Montalban et al 2025) or diagnosis of relapsing, active SPMS according to Lublin et al 2014.
  5. Participants should have an EDSS of ≤ 6.5 at screening.
  6. Evidence of active disease (clinical relapses and MRI activities within 2 years prior to screening) while on a high efficacy disease-modifying therapy for ≥ 6 months.

    PMS Cohort Specific Inclusion Criteria

  7. Diagnosis of PPMS according to the 2024 McDonald Criteria (Montalban et al 2025) or non-relapsing SPMS according to Lublin et al 2014.
  8. Participants must have an EDSS of ≥ 3.0 and ≤ 6.5 at screening.
  9. Inadequate response ≥ 1 heDMT with ≥ 6 months treatment.

Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:

  1. Any prior CAR-T or CAR-NK cell exposure.
  2. Underwent splenectomy within 12 months prior to signing the ICF.
  3. Received a solid organ transplant at any time or on an active transplant waiting list.
  4. Prior treatment with hematopoietic stem cell transplantation or total lymphoid irradiation.
  5. Cardiac conditions or any other significant cardiac condition that would present undue risk to the participant in the investigator's opinion:
  6. Any other central nervous system disease including epilepsy, convulsive seizures, organic encephalopathy syndrome, non-MS related paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease or associated movement disorder, psychosis, CNS vasculitis, or any other neurological disease that may impact the ability to evaluate neurotoxicity. History of a seizure disorder even if the seizure disorder is well controlled with anti-epileptics.
  7. Participant has significant psychiatric condition (active or history of).
  8. History of other immune-mediated disease that required continued systemic /systemic disease-modifying agents.
  9. Evidence of bleeding or active bleeding diathesis within 90 days before screening
  10. History of or ongoing treatment for prior malignancy.
  11. Inborn error of immunity and/or primary immunodeficiency.
  12. Seropositive for or HTLV (including any history of HIV or HTLV).
  13. Active viral (any etiology, , ) hepatitis are excluded.
  14. Major surgery within 4 weeks prior to apheresis or lymphodepletion or has surgery planned during the study or within 4 weeks after study treatment administration.
  15. Pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 1 year after receiving study treatment, whichever is longer.
  16. Unwilling or unsafe to proceed with CSF exams based on coagulopathy or anatomy or other considerations in the judgment of the study investigator.
  17. Any to LP.
  18. Participants not willing, able, or are unsafe to take MRI scans as per protocol.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Arm/Group 1: AZD0120 RMS

    AZD0120 RMS

    Biological: AZD0120 - Regimen 1 · Biological: AZD0120 - Regimen 2

  • Experimental
    Arm/Group 2: AZD0120 PMS

    AZD0120 PMS

    Biological: AZD0120 - Regimen 1 · Biological: AZD0120 - Regimen 2

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS)

    Incidence and severity of Dose Limiting Toxicity (DLT) through Day 29 following AZD0120 administration.

    Time frame: Day 1 to day 29

  2. Evaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS)

    Incidence and severity of Adverse Events (AE) over 104 weeks following AZD0120 administration.

    Time frame: Day 1 to day 29, and over 104 weeks

  3. Evaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS)

    Incidence and severity of Serious Adverse Events (SAE) over 104 weeks following AZD0120 administration.

    Time frame: Day 1 to day 29, and over 104 weeks

  4. Evaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS)

    Incidence and severity of Treatment Emergent Adverse Events (TEAE) over 104 weeks following AZD0120 administration.

    Time frame: Day 1 to day 29, and over 104 weeks

Secondary outcomes

  1. Evaluate the optimum regimen with AZD0120 in MS participants to determine the RP2D in each disease cohort

    Change from baseline in peripheral B-cell counts following AZD0120 administration

    Time frame: Over 104 weeks

  2. Evaluate the optimum regimen with AZD0120 in MS participants to determine the RP2D in each disease cohort

    CK parameters in peripheral B-cell counts following AZD0120 administration

    Time frame: Over 104 weeks

  3. Evaluate the preliminary efficacy of AZD0120 in RMS and PMS

    Annualized Relapse Rate (ARR) over 104 weeks (RMS cohort only)

    Time frame: Over 104 weeks

  4. Evaluate the preliminary efficacy of AZD0120 in RMS and PMS

    Time to onset participants with CDP-12 over 104 weeks

    Time frame: Over 104 weeks

  5. Evaluate the preliminary efficacy of AZD0120 in RMS and PMS

    Proportion of participants with CDP-12 over 104 weeks

    Time frame: Over 104 weeks

  6. Evaluate the preliminary efficacy of AZD0120 in RMS and PMS

    Time to onset participants with CDP-24 over 104 weeks

    Time frame: Over 104 weeks

  7. Evaluate the preliminary efficacy of AZD0120 in RMS and PMS

    Proportion of participants with CDP-24 over 104 weeks

    Time frame: Over 104 weeks

  8. Evaluate the preliminary efficacy of AZD0120 in RMS and PMS

    Proportion of participants achieving CDI

    Time frame: Over 104 weeks

  9. Evaluate the preliminary efficacy of AZD0120 in RMS and PMS

    Change from baseline in 9HPT (9-Hole Peg Test)

    Time frame: Over 104 weeks

  10. Evaluate the preliminary efficacy of AZD0120 in RMS and PMS

    Change from baseline in T25FW (Timed 25-Foot Walk)

    Time frame: Over 104 weeks

  11. Evaluate the preliminary efficacy of AZD0120 in RMS and PMS

    Change from baseline in EDSS (Expanded Disability Status Scale)

    Time frame: Over 104 weeks

  12. Evaluate the preliminary efficacy of AZD0120 in RMS and PMS

    Change from baseline in SDMT (Symbol Digit Modalities Test)

    Time frame: Over 104 weeks

  13. Evaluate the preliminary efficacy of AZD0120 in RMS and PMS

    Proportion of participants with NEDA-3 (No Evidence of Disease Activity)

    Time frame: Over 104 weeks

  14. Evaluate the preliminary efficacy of AZD0120 in RMS and PMS

    Proportion of participants with PIRA (Progression Independent of Relapse Activity)

    Time frame: Over 104 weeks

  15. Evaluate the preliminary efficacy of AZD0120 in RMS and PMS

    Change from screening in MRI parameters including: mean number of Gd+ T1 lesions over time

    Time frame: Over 104 weeks

  16. Evaluate the preliminary efficacy of AZD0120 in RMS and PMS

    Change from screening in MRI parameters including: mean number of new or enlarging T2 hyperintense lesions

    Time frame: Over 104 weeks

  17. Evaluate the preliminary efficacy of AZD0120 in RMS and PMS

    Change from screening in MRI parameters including brain volume

    Time frame: Over 104 weeks

  18. Evaluate the preliminary efficacy of AZD0120 in RMS and PMS

    Change in MRI parameters including: mean number of Gd+ T1 lesions over time.

    Time frame: Over 104 weeks

  19. Evaluate the preliminary efficacy of AZD0120 in RMS and PMS

    Change in MRI parameters including: mean number of new or enlarging T2 hyperintense lesions

    Time frame: Over 104 weeks

  20. Investigate the effects of AZD0120 on the function and quality of life of participants with MS

    Change in SF-36v2 from baseline

    Time frame: Over 104 weeks

  21. Investigate the effects of AZD0120 on the function and quality of life of participants with MS

    Change in Neuro-QoL-fatigue from baseline

    Time frame: Over 104 weeks

  22. Characterize the CK and PD of AZD0120 in participants with MS

    Quantification of CAR transgene levels of AZD0120 in blood and CSF.

    Time frame: Over 104 weeks

  23. Characterize the CK and PD of AZD0120 in participants with MS

    Cmax

    Time frame: Over 104 weeks

  24. Characterize the CK and PD of AZD0120 in participants with MS

    AUC(0-28).

    Time frame: Over 104 weeks

  25. Characterize the CK and PD of AZD0120 in participants with MS

    AUClast.

    Time frame: Over 104 weeks

  26. Characterize the CK and PD of AZD0120 in participants with MS

    Clast.

    Time frame: Over 104 weeks

  27. Characterize the CK and PD of AZD0120 in participants with MS

    Tmax.

    Time frame: Over 104 weeks

  28. Characterize the CK and PD of AZD0120 in participants with MS

    Tlast.

    Time frame: Over 104 weeks

  29. Characterize the CK and PD of AZD0120 in participants with MS

    B-cell counts

    Time frame: Over 104 weeks

  30. To monitor the incidence of vector-derived RCL

    Proportion of participants with detectable RCL at pre-specified post infusion timepoints

    Time frame: Over 104 weeks

  31. To assess the immunogenicity of AZD0120 in participants.

    Proportion of participants who develop anti- AZD0120 antibodies

    Time frame: over 104 weeks

  32. To assess the immunogenicity of AZD0120 in participants.

    Time to development of anti-AZD0120 antibodies

    Time frame: over 104 weeks

  33. To assess the immunogenicity of AZD0120 in participants.

    Changes in anti-AZD0120 antibody titers over 104 weeks

    Time frame: over 104 weeks

07

Study locations

7 of 20 sites recruiting
  • Research Site
    Tucson, Arizona 85719, United States
    Withdrawn

    Not enrolling at this site.

  • Research Site
    Aurora, Colorado 80045, United States
    Not yet recruiting
  • Research Site
    Washington D.C., District of Columbia 20010, United States
    Recruiting
  • Research Site
    Chicago, Illinois 60611, United States
    Not yet recruiting
  • Research Site
    St Louis, Missouri 63110, United States
    Recruiting
  • Research Site
    New York, New York 10016, United States
    Recruiting
  • Research Site
    New York, New York 10032, United States
    Recruiting
  • Research Site
    Cleveland, Ohio 44195, United States
    Not yet recruiting
  • Research Site
    Seattle, Washington 98122, United States
    Recruiting
  • Research Site
    Milwaukee, Wisconsin 53226, United States
    Recruiting
  • Research Site
    Liverpool, 2170, Australia
    Not yet recruiting
  • Research Site
    Melbourne, 3000, Australia
    Recruiting
  • Research Site
    Melbourne, 3004, Australia
    Not yet recruiting
  • Research Site
    Waratah, 2298, Australia
    Not yet recruiting
  • Research Site
    Montreal, Quebec H3A 1A1, Canada
    Not yet recruiting
  • Research Site
    Leipzig, 04103, Germany
    Withdrawn

    Not enrolling at this site.

  • Research Site
    Magdeburg, 39120, Germany
    Withdrawn

    Not enrolling at this site.

  • Research Site
    Würzburg, DE-97072, Germany
    Withdrawn

    Not enrolling at this site.

  • Research Site
    Cambridge, CB2 2QQ, United Kingdom
    Withdrawn

    Not enrolling at this site.

  • Research Site
    London, SE5 9RS, United Kingdom
    Withdrawn

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2028, 36 months after the start.

Of 39 industry-sponsored phase 1 interventional studies under Multiple Sclerosis, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 32. This study's planned 36 months is above that.

Counting every sponsor, half of 92 studies reached it within 30 months; a quarter within 9 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2025
First posted
Nov 4, 2025
StartActual
Dec 9, 2025
Primary completionEst.
Dec 12, 2028
CompletionEst.
Dec 12, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Research Site · Chicago, United States
Nov 17, 2026
Eligibility
2 criteria edited
What changed in the criteria
  • EditedEvidence of active disease (clinical relapses and MRI activities within 2 years prior to screening), or intolerance, while on a high efficacy disease-modifying therapy for ≥ 6 months.
  • EditedInadequate response ≥ 1 heDMT with ≥ 6 months treatment or intolerance.
Nov 17, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameEvaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS)Day 1 to day 29, and over 104 weeks → Day 1 to day 29
  • DescriptionEvaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS): how it is measured was reworded
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    1 site added
    Show site
    • Research Site · Chicago, United States
    Eligibility 2 criteria edited
    What changed in the criteria
    • EditedEvidence of active disease (clinical relapses and MRI activities within 2 years prior to screening), or intolerance, while on a high efficacy disease-modifying therapy for ≥ 6 months.
    • EditedInadequate response ≥ 1 heDMT with ≥ 6 months treatment or intolerance.
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameEvaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS)Day 1 to day 29, and over 104 weeks → Day 1 to day 29
    • DescriptionEvaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS): how it is measured was reworded
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07224373
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 4, 2025
Start date
Dec 9, 2025
Primary completion
Dec 12, 2028 (estimated)
Completion
Dec 12, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F

Start the discussion